Logo Lanfrica
  • Accueil
  • Atlas
  • Analyses
  • Documentation
  • Sign in

© 2026 Lanfrica. Tous droits réservés. Tous les droits d'auteur des ressources affichées sur le site Web Lanfrica appartiennent aux détenteurs de droits d'auteur d'origine, sauf indication contraire explicite.

Tornado diagram of one-way sensitivity analyses when ART-eligibility threshold is at CD4 count ≤250/µl.

Domaine:

healthcare

Type de record:

paper
Créateur:
EmiIleJonAma
Hôte:avatar

A range of parameters varied in one-way sensitivity analyses are displayed on the vertical axis. The ICER (US dollars/YLS) of POC-CD4 compared to LAB-CD4 is represented on the x-axis. The solid vertical line indicates the ICER of the base case (US$500/YLS). The dashed vertical line represents the per capita GDP of Mozambique (MOZ GDP), i.e., the “very cost-effective” threshold; the dotted vertical line represents three times GDP, i.e., the “cost-effective” threshold. For each parameter, the horizontal bar represents the range of ICERs that result from varying that parameter along the range of values indicated in the parentheses; the first value listed in the parentheses is the one that results in the lowest ICER. Of all one-way sensitivity analyses, the ICER of POC-CD4 compared to LAB-CD4 crosses the cost-effectiveness threshold (into the area of not being cost-effective) (US$1,710/YLS) only when point-of-care CD4 test cost is>US$1,100/test or when repeat HIV testing or immunologic staging are completed every 9 mo or more frequently.

Visit

figshare.com

Tags

Uncategorisedsensitivity analysesimpactsurvivalHIV testingHIV diagnosislinkageicermozambiqueYLS+5

Licenses

CC BY 4.0

Similaires

Median CD4 count (cells/µl) and interquartile range, from ART initiation in the HIV-2 cohort, IeDEA West Africa collaboration.Effects, cost, and cost-effectiveness of universal test and treat versus continued scale-up of ART at CD4 count ≤350 cells/µl in South Africa over the period 2012–2050 (Model D).Cumulative net costs and cumulative number of life-years saved of universal testing and immediate ART for all HIV-infected patients (UTT) compared to the current rollout in South Africa of ART at CD4 count ≤350 cells/µl, as predicted with model D.Cumulative incidence of mortality up to four years after start of ART by region and CD4 count at ART initiation, corrected in South Africa for mortality under-ascertainment.SHIMS CD4 Count Cohort (Cohort C)Selected sensitivity analyses.

Median CD4 count (cells/µl) and interquartile range, from ART initiation in the HIV-2 cohort, IeDEA West Africa collaboration.

Median CD4 count (cells/µl) and interquartile range, from ART initiation in the HIV-2 cohort, IeD

Effects, cost, and cost-effectiveness of universal test and treat versus continued scale-up of ART at CD4 count ≤350 cells/µl in South Africa over the period 2012–2050 (Model D).

Costs and effects are discounted at an annual rate of 3%. Life-years concern the total life-years

Cumulative net costs and cumulative number of life-years saved of universal testing and immediate ART for all HIV-infected patients (UTT) compared to the current rollout in South Africa of ART at CD4 count ≤350 cells/µl, as predicted with model D.

(A) Cumulative net costs; (B) cumulative number of life-years saved. Grey lines represent 100 ind

Cumulative incidence of mortality up to four years after start of ART by region and CD4 count at ART initiation, corrected in South Africa for mortality under-ascertainment.

Cumulative incidence of mortality up to four years after start of ART by region and CD4 count at

SHIMS CD4 Count Cohort (Cohort C)

Swaziland HIV Incidence Measurement Survey CD4 count cohort dataset

Selected sensitivity analyses.

Sensitivity of the model for the prevalence of tuberculosis, for the prevalence of multidrug-resi